- Organizations: Novartis
Products
Bausch + Lomb officially acquires Xiidra from Novartis
The $2.5 billion-deal also includes two “front-of-eye” assets.
Pipeline
Novartis halts clinical development of GA gene therapy
Decision to end GT005 development will result in write-off milestone payments of over $68 million.
Products
Bausch + Lomb to acquire Xiidra from Novartis
Deal is worth up to $2.5 billion; includes AcuStream delivery technology and two investigational compounds for chronic ocular surface pain.
Products
Harrow launches three ophthalmic medicines in US
Company officially transfers NDAs for Ilevro, Nevanec, and Maxidex.
Research
Rare retinal side effects reported following Novartis AMD drug use
Two studies assess causes behind reports of retinal vasculitis and retinal vascular occlusion.
Business
Novartis is (reportedly) starting to sell its ophthalmology assets
Bloomberg reports that Novartis AG is working with an adviser to determine potential sales for its front-of-eye treatment assets.
Products
Generic version of Durezol launches in US
Dr. Reddy’s Laboratories formulation is now another competitive option for treating postoperative inflammation and pain associated with ocular surgery and endogenous anterior uveitis.
Legal
Court sides with Regeneron in Eylea patent case against Novartis
Novartis claimed Regeneron’s Eylea (aflibercept) delivery system was in violation of its patent for Lucentis (ranibizumab), a competing AMD drug.
Products
Harrow completes acquisition of exclusive US rights for 5 ophthalmic products
Deal is worth up to $175 million; includes an additional payout upon the commercial availability of Triesence later this year.
Business
Harrow to acquire US rights to 5 ophthalmic products from Novartis
Acquisition marks the second deal between the two companies in less than a year.
Business
Is Novartis selling its ophthalmology franchise?
A Bloomberg report claims Novartis AG is in the early stages of considering selling its ophthalmology and respiratory units in order to invest in cutting-edge medicines.
Archives